{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:17:01Z","timestamp":1791649021303,"version":"4.3.4"},"reference-count":30,"publisher":"American Chemical Society (ACS)","issue":"4","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ak0101074"],"award-info":[{"award-number":["JP17ak0101074"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2021,4,5]]},"DOI":"10.1021\/acs.molpharmaceut.0c01207","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T15:19:30Z","timestamp":1614266370000},"page":"1711-1719","source":"Crossref","is-referenced-by-count":16,"title":["In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration"],"prefix":"10.1021","volume":"18","author":[{"given":"Toshihide","family":"Takagi","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University, 45\u22121 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Masada","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University, 45\u22121 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9361","authenticated-orcid":true,"given":"Keiko","family":"Minami","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University, 45\u22121 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5349-3174","authenticated-orcid":true,"given":"Makoto","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University, 45\u22121 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Izutsu","sequence":"additional","affiliation":[{"name":"National Institute of Health Sciences, Kawasaki, Kanagawa 210-9501, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Sawai Pharmaceutical Co. Ltd, Osaka 532-0003, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-9958","authenticated-orcid":true,"given":"Shinji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Setsunan University, 45\u22121 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"ref1\/cit1","volume-title":"Guidance for Industry, Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs \u2013 General Considerations","year":"2014"},{"key":"ref2\/cit2","volume-title":"Guideline, the investigation of bioequivalence. Committee for Medicinal Products for Human Use (CHMP)","year":"2010"},{"key":"ref3\/cit3","volume-title":"National Institute of Health Sciences Guideline, bioequivalence studies of generic products","year":"2012"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24112"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.09.002"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00135"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00824"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0231-8"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.03.013"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.06.018"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12951"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1021\/mp100116g"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1021\/mp500196f"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00602"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02651.x"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1975.sp010841"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.2174\/1874467210666170224095741"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.05.033"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.08.028"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.267"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.04.013"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600820902"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018970323716"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1136\/gut.27.8.886"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015827908309"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0931-1"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0217-6"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1021\/mp400426f"},{"key":"ref29\/cit29","doi-asserted-by":"crossref","unstructured":"Sugano, K. Theoretical framework II: Dissolution. In Biopharmaceutics Modeling and Simulations Theory, Practice, Methods, and Applications; John Wiley & Sons, Inc.: New Jersey, 2012; 33\u201363.","DOI":"10.1002\/9781118354339.ch3"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.05.009"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.0c01207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T19:51:57Z","timestamp":1682625117000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.0c01207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,5]]}},"alternative-id":["10.1021\/acs.molpharmaceut.0c01207"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c01207","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}